Joana Spaggiari Marra1,2, Guilherme Paulão Mendes3,4, Gerson Hiroshi Yoshinari5, Flávio da Silva Guimarães3,1, Suleimy Cristina Mazin6, Harley Francisco de Oliveira5,6,7,8. 1. Department of Radiation Oncology, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. 2. Department of Radiation Oncology, Hospital Regional do Cancer de Passos, Passos, MG, Brazil. 3. Department of Radiation Oncology, Centro de Radioterapia de São Carlos, São Carlos, SP, Brazil. 4. Department of Radiation Oncology, Serviço de Radioterapia da Santa Casa de Araraquara, Araraquara, SP, Brazil. 5. Department of Radiation Oncology, Hospital Márcio Cunha, Fundação São Francisco Xavier, Ipatinga, MG, Brazil. 6. Department of Gynaecology and Obstetrics, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto - SP, Brazil. 7. Department of Radiation Oncology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. 8. Department of Radiation Oncology, Centro de Tratamento em Radio-oncologia, Ribeirão Preto, SP, Brazil.
Abstract
BACKGROUND: High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy. AIM: To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy. MATERIALS AND METHODS: Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively. RESULTS: Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27-123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes. CONCLUSIONS: Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p < 0.05). The estimated overall survival was 18 months (Kaplan-Meier estimator). Our results corroborated those reported in the literature.
BACKGROUND: High-grade gliomas (HGGs) are a heterogeneous disease group, with variable prognosis, inevitably causing deterioration of the quality of life. The estimated 2-year overall survival is 20%, despite the best trimodality treatment consisting of surgery, chemotherapy, and radiotherapy. AIM: To evaluate long-term survival outcomes and factors influencing the survival of patients with high-grade gliomas treated with radiotherapy. MATERIALS AND METHODS: Data from 47 patients diagnosed with high-grade gliomas between 2009 and 2014 and treated with three-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT) were analyzed retrospectively. RESULTS: Median survival was 16.6 months; 29 patients (62%) died before the time of analysis. IMRT was employed in 68% of cases. The mean duration of radiotherapy was 56 days, and the mean delay to the start of radiotherapy was 61.7 days (range, 27-123 days). There were no statistically significant effects of duration of radiotherapy or delay to the start of radiotherapy on patient outcomes. CONCLUSIONS: Age, total amount of gross resection, histological type, and use of adjuvant temozolomide influenced survival rate (p < 0.05). The estimated overall survival was 18 months (Kaplan-Meier estimator). Our results corroborated those reported in the literature.
Authors: Ulrich Hermanto; Erik K Frija; Mingfwu J Lii; Eric L Chang; Anita Mahajan; Shiao Y Woo Journal: Int J Radiat Oncol Biol Phys Date: 2007-01-08 Impact factor: 7.038
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: Michael G Hart; Robert Grant; Ruth Garside; Gabriel Rogers; Margaret Somerville; Ken Stein Journal: Cochrane Database Syst Rev Date: 2008-10-08